Clinical Trial

PDMC Implementation Trial in Kenya

Study acronym: PDMC-SL
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this implementation trial is to evaluate at least two alternative delivery strategies and adherence support for malaria chemoprevention with dihydroartemisinin-piperaquine in the post-discharge management of children hospitalised with severe anaemia or severe malaria to optimise adherence in Kenya. The actual interventions to be evaluated have been co-designed with national stakeholders during an initial formative research stage.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-01; most recent amendment 2025-11-18.
Status change: Not Yet Recruiting → Recruiting 2025-09-30
Trial Details
NCT Number NCT06624631
Lead Sponsor Liverpool School of Tropical Medicine
Collaborators: Kenya Medical Research Institute, Institut de Recherche Clinique du Benin, Epicentre, Paris, France and Mbarara University of Science and Technology, Faculty of Medicine, Mbarara, Uganda, Institute of Research for Development, France, Training Research Unit of Excellence, Blantyre, Malawi, Makerere University, Centres for Disease Control and Prevention, Kenya.
Conditions Severe Malaria, Severe Anemia
Enrollment 600 participants
Start Date 2025-09-05
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-21